May 21, 2021 07:19 AM EDT
Pharma
FDA+

Eli Lil­ly sues HHS to halt any 340B-re­lat­ed mon­e­tary penal­ties

Zachary Brennan

Senior Editor

The Biden ad­min­is­tra­tion’s fight with drug­mak­ers over a drug dis­count pro­gram, known as 340B, is start­ing to boil over.

Just days af­ter HHS set a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times